Literature DB >> 9531379

Cellular and molecular mechanisms of radiation inhibition of restenosis. Part I: role of the macrophage and platelet-derived growth factor.

P Rubin1, J P Williams, P N Riggs, S Bartos, T Sarac, R Pomerantz, J Castano, M Schell, R M Green.   

Abstract

PURPOSE: The major radiobiological issue in determining the rationale for the use of radiation to inhibit vascular restenosis is the identification of the target cell(s) and/or cytokine(s) responsible for neointimal hyperplasia and vascular remodeling. The central hypothesis of this report is that the macrophage/monocyte and PDGF are key elements in the process of neointimal hyperplasia seen following angioplasty, similar to their role in lesion formation and progression found in atherosclerotic thickening. Specific immunohistochemical and cytochemical stains were applied to a rat carotid model in a temporal series after balloon angioplasty to determine macrophage activity vs. smooth muscle cell proliferation, the latter being classically thought to be the cell responsible for restenosis. METHODS AND MATERIALS: Neointimal hyperplasia was created in an established rat carotid artery model by a balloon catheter technique. Immediately following injury, treatment groups received irradiation via high dose rate (HDR) brachytherapy, the 192Ir source being placed externally to the vessel. Radiation was delivered to a length of 2 cm of the injured vessel at doses of 5, 10, and 15 Gy, and the animals were sacrificed at various time points following treatment (24 h to 6 months). Serial sections of tissue were stained immunohistochemically with the primary antibodies CD11b, mac-1, anti-PDGF, and alpha-smooth muscle actin.
RESULTS: Immediately (24 h) postinjury, there is an apparent migration of macrophages seen in the adventitia; after 1 week, proliferation and migration of macrophages could be seen clearly within all the vessel layers, especially in the intima; by 3 weeks, when there was evidence of neointimal hyperplasia, macrophages could still be seen, mainly in the intima scattered among the smooth muscle cells and myofibroblasts, and to a lesser degree at 6 months. There was corresponding expression of PDGF, whenever and wherever there were zones of activation/neointimal hyperplasia. Alpha-smooth muscle actin staining identified the smooth muscle cells distinct from the macrophages, and these SMCs exhibited activation in the neointimal hyperplasia zones at all later time points. Furthermore, we showed that radiation significantly reduced the macrophage population, while the onset of neointimal hyperplasia was accompanied by a return of the macrophage population.
CONCLUSION: Our results suggest that the activated adventitial macrophage/monocyte are the key cells responsible for initiating the arterial neointimal hyperplasia and vascular remodeling developing postangioplasty as they are in the initiation and perpetuation of atheromatous thickening. Irradiation delivered immediately postinjury is, therefore, highly effective, because the macrophage population is exquisitely radiosensitive.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531379     DOI: 10.1016/s0360-3016(97)00937-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

Review 1.  Early and late effects of radiation treatment for prevention of coronary restenosis: a critical appraisal.

Authors:  O F Bertrand; S Lehnert; R Mongrain; M G Bourassa
Journal:  Heart       Date:  1999-12       Impact factor: 5.994

2.  Intravascular radiotherapy: restenosis and more?

Authors:  P Wexberg; M Gottsauner-Wolf
Journal:  Heart       Date:  2000-05       Impact factor: 5.994

3.  An organotypical in vitro model for vascular tissue remodelling and its application to study radiation effects.

Authors:  M Verbeke; H Thierens; Y Taeymans; L De Ridder
Journal:  Cytotechnology       Date:  2000-11       Impact factor: 2.058

Review 4.  Endovascular brachytherapy--treatment planning and radiation protection.

Authors:  U Quast; D Flühs; M Bambynek
Journal:  Herz       Date:  1998-09       Impact factor: 1.443

5.  Endovascular Brachytherapy in Peripheral Arteries: Solution for Restenosis or False Hope?

Authors:  Boris Pokrajac; Roswitha Wolfram; Brigitte Lileg; Erich Minar
Journal:  Curr Treat Options Cardiovasc Med       Date:  2003-04

6.  Adventitial response to intravascular brachytherapy in a rabbit model of restenosis.

Authors:  Paul Wexberg; Konrad Mück; Ursula Windberger; Susanna Lang; Martin Osranek; Franz Weidinger; Gerald Maurer; Michael Gottsauner-Wolf
Journal:  Wien Klin Wochenschr       Date:  2004-03-31       Impact factor: 1.704

7.  From basic biology to randomized clinical trial: the Beta Radiation for Arteriovenous Graft Outflow Stenosis (BRAVO II).

Authors:  Prabir Roy-Chaudhury; Perry Arnold; Jeff Seigel; Sanjay Misra
Journal:  Semin Dial       Date:  2012-10-16       Impact factor: 3.455

8.  Development and pre-clinical test of a phosphorous-32 containing polyetheretherketone foil aiming at urethral stricture prevention by low-dose-rate brachytherapy.

Authors:  Walter Assmann; Ricarda Becker; Christian Stief; Ronald Sroka
Journal:  J Contemp Brachytherapy       Date:  2022-04-02

9.  Transplantation of EPCs overexpressing PDGFR-β promotes vascular repair in the early phase after vascular injury.

Authors:  Hang Wang; Yang-Guang Yin; Hao Huang; Xiao-Hui Zhao; Jie Yu; Qiang Wang; Wei Li; Ke-Yin Cai; Shi-Fang Ding
Journal:  BMC Cardiovasc Disord       Date:  2016-09-13       Impact factor: 2.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.